Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
120
Recruiting, industry sponsors, Neurology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting120
- Completed845
120 trials
Showing 1 to 25, recently updated first.
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07889349 · 50 participants (planned) · Start Nov 9, 2026 · Primary completion Jan 2027
Drug: SHR 3201 Injection; SHR 3201 Placebo. · For: Alzheimer's Disease
Sites: Hefei, China
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
- A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07843459 · 111 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 2028
Drug: LY4560736; LY4560736 and 2 more · For: Healthy Volunteers; Alzheimer Disease; Amyloid and 2 more
Sites: Anaheim, California; Irvine, California; Los Alamitos, California · 19 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07214727 · 50 participants (planned) · Start Oct 15, 2025 · Primary completion Mar 6, 2030
Drug: ALN-5288; Placebo · For: Alzheimer's Disease
Sites: Montreal, Canada; Ottawa, Canada; Toronto, Canada · 13 sites in all
Faeth TherapeuticsIndustry
NCT07558733 · 32 participants (planned) · Start Apr 22, 2026 · Primary completion May 2029
Drug: Serabelisib; Sapanisertib and 1 more · For: HR+ HER2- Breast Cancer
Sites: Los Angeles, California; Newport Beach, California; Lone Tree, Colorado · 9 sites in all
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07304154 · 57 participants (planned) · Start Apr 10, 2026 · Primary completion Dec 2031
Drug: KITE-363; Fludarabine and 1 more · For: Chronic Inflammatory Demyelinating Polyneuropathy; Myasthenia Gravis; Multiple Sclerosis
Sites: Newport Beach, California; Palo Alto, California; New York, New York · 10 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07224373 · 24 participants (planned) · Start Dec 9, 2025 · Primary completion Dec 12, 2028
Drug: AZD0120 - Regimen 1; AZD0120 - Regimen 2 · For: Multiple Sclerosis
Sites: Tucson, Arizona; Aurora, Colorado; Washington D.C., District of Columbia · 20 sites in all
- A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerRecruiting
Totus MedicinesIndustry
NCT05683418 · 241 participants (planned) · Start Feb 15, 2023 · Primary completion Dec 2027
Drug: TOS-358; Fulvestrant and 2 more · For: HR+/HER2-negative Breast Cancer
Sites: Los Angeles, California; San Francisco, California; St. Petersburg, Florida · 25 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07787182 · 68 participants (planned) · Start Oct 10, 2026 · Primary completion Jan 2028
Drug: LY4405094; LY4405094 and 2 more · For: Healthy Volunteers; Alzheimer Disease; Amyloid and 1 more
Sites: Anaheim, California; Irvine, California; Los Alamitos, California · 19 sites in all
argenxargenx (ARGX)
NCT07610564 · 60 participants (planned) · Start Jul 27, 2026 · Primary completion Feb 1, 2028
Drug: Empasiprubart IV · For: Multifocal Motor Neuropathy (MMN)
Sites: New Haven, Connecticut; Tbilisi, Georgia · 5 sites in all
Zhuhai Hengqin ImStem Biotechnology Co., Ltd.Industry
NCT07935031 · 4 participants (planned) · Start Sep 28, 2026 · Primary completion Dec 2027
Drug: IMS001 · For: Multiple Sclerosis
Sites: Chengdu, China
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06469944 · 160 participants (planned) · Start Sep 20, 2024 · Primary completion Sep 12, 2029
Drug: Pembrolizumab; Sacituzumab Tirumotecan (sac-TMT) and 6 more · For: Gastroesophageal Junction; Gastroesophageal Adenocarcinoma; Esophageal Neoplasms and 1 more
Sites: Tucson, Arizona; Los Angeles, California; Louisville, Kentucky · 50 sites in all
Vector Y TherapeuticsIndustry
NCT07287397 · 36 participants (planned) · Start Dec 19, 2025 · Primary completion Oct 15, 2027
Drug: Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; San Diego, California; Jacksonville, Florida · 9 sites in all
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
Serina TherapeuticsIndustry
NCT07422675 · 40 participants (planned) · Start Feb 1, 2026 · Primary completion Jan 31, 2027
Drug: SER-252 (PEOZ-apomorphine) · For: PARKINSON DISEASE (Disorder); Advanced Parkinson's Disease
Sites: Englewood, Colorado; Hallandale, Florida; Maitland, Florida · 8 sites in all
BiogenBiogen (BIIB)
NCT07855211 · 69 participants (planned) · Start Oct 7, 2026 · Primary completion Jan 23, 2034
Drug: BIIB147; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Scottsdale, Arizona; St Louis, Missouri; Austin, Texas
Acta PharmaceuticalsIndustry
NCT07690228 · 72 participants (planned) · Start Sep 23, 2026 · Primary completion Nov 2027
Drug: GSM-779690T; Placebo · For: Healthy Adult Participants; Alzheimer Disease
Sites: Melbourne, Australia
Consano BioIndustry
NCT07264270 · 24 participants (planned) · Start Dec 3, 2025 · Primary completion Jun 2027
Drug: C-1101 · For: Lumbosacral Radicular Pain; Sciatic Radiculopathy; Sciatic Leg Pain and 3 more
Sites: Fernandina Beach, Florida; Winston-Salem, North Carolina; Richmond, Virginia · 6 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT05231785 · 60 participants (planned) · Start Feb 4, 2022 · Primary completion Jan 11, 2029
Drug: ALN-APP; Placebo · For: Early-Onset Alzheimer Disease
Sites: La Jolla, California; Indianapolis, Indiana; Montreal, Canada · 8 sites in all
- Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary TauopathiesPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT07221344 · 160 participants (planned) · Start Nov 18, 2025 · Primary completion Jun 2027
Drug: ARO-MAPT-SC; Placebo · For: Alzheimer Disease; Tauopathies; Frontotemporal Dementia and 1 more
Sites: East York, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
Rapport Therapeutics Inc.Industry
NCT07923097 · 60 participants (planned) · Start Nov 2026 · Primary completion Jun 2027
Drug: RAP-219 or Placebo · For: Epilepsy
Sites: Adelaide, Australia
- A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's DiseasePivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07787169 · 179 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 2028
Drug: LY4405094; LY4405094 and 2 more · For: Alzheimer Disease; Amyloid; Plaque, Amyloid and 1 more
Sites: Anaheim, California; Irvine, California; Los Alamitos, California · 19 sites in all
Innopeutics CorporationIndustry
NCT07371338 · 6 participants (planned) · Start May 13, 2026 · Primary completion Jun 30, 2028
Drug: IPS101A · For: Parkinson Disease; Parkinson's Disease
Sites: Seoul, South Korea
Eli Lilly and CompanyEli Lilly (LLY)
NCT07100119 · 36 participants (planned) · Start Aug 5, 2025 · Primary completion Aug 2027
Drug: LY4256984; Placebo · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Leuven, Belgium; Calgary, Canada; Edmonton, Canada · 12 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.